Principal Active High Yield ETF

19.01

0.0000

Post-market: 19.010.00000.00%16:10 EDT

Volume:102.85K

Turnover:1.95M

Market Cap:544.64M

PE:- -

High:19.04

Open:18.99

Low:18.98

Close:19.01

52wk High:19.48

52wk Low:18.68

Shares:28.65M

Float Shares:28.65M

Volume Ratio:0.59

T/O Rate:0.36%

Dividend:1.39

Dividend Rate:7.30%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)

prnewswire

·

Apr 20

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/YLD"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"YLD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"YLD\",,,,,undefined,":{"symbol":"YLD","market":"US","secType":"STK","nameCN":"Principal Active High Yield ETF","latestPrice":19.01,"timestamp":1778788800000,"preClose":19.01,"halted":0,"volume":102849,"hourTrading":{"tag":"盘后","latestPrice":19.01,"preClose":19.01,"latestTime":"16:10 EDT","volume":10,"amount":190.10000000000002,"timestamp":1778789404539,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":28650000,"shares":28650000,"eps":0,"marketStatus":"Post-Mkt","change":0,"latestTime":"05-14 18:23:58 EDT","open":18.99,"high":19.04,"low":18.98,"amount":1954012.66376,"amplitude":0.003156,"askPrice":20.63,"askSize":100,"bidPrice":18.76,"bidSize":132,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1778803200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":19.01,"sharesOutstanding":25550000,"nav":18.949797,"aum":541732955.17,"dividendRate":0.072962,"bidAskSpread":0.000792,"postHourTrading":{"tag":"盘后","latestPrice":19.01,"preClose":19.01,"latestTime":"16:10 EDT","volume":10,"amount":190.10000000000002,"timestamp":1778789404539,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.588682,"impliedVol":0.0733,"impliedVolPercentile":0.0677},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"YLD\",,,,,undefined,":{"symbol":"YLD","floatShares":28650000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.588682,"shares":28650000,"dividePrice":1.387,"high":19.04,"amplitude":0.003156,"preClose":19.01,"low":18.98,"week52Low":18.675,"pbRate":"--","week52High":19.48,"institutionHeld":0,"latestPrice":19.01,"committee":0.137931,"eps":0,"divideRate":0.072962,"volume":102849,"delay":0,"ttmEps":0,"open":18.99,"prevYearClose":19.005,"prevWeekClose":19.07,"prevMonthClose":19.06,"prevQuarterClose":18.96,"fiveDayClose":19.02,"twentyDayClose":19.01,"sixtyDayClose":19.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/YLD\",params:#limit:5,,,undefined,":[{"date":"2026-05-01","symbol":"YLD","amount":0.113732,"announcedDate":"2026-04-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Principal Active High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-05","payableDate":"2026-05-01","currency":"USD","dateTimestamp":1777608000000,"payDate":"2026-05-05"},{"date":"2026-04-01","symbol":"YLD","amount":0.116138,"announcedDate":"2026-03-31","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-01","defaultRemindTime":1775050200000,"name":"Principal Active High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-06","payableDate":"2026-04-01","currency":"USD","dateTimestamp":1775016000000,"payDate":"2026-04-06"},{"date":"2026-03-02","symbol":"YLD","amount":0.111621,"announcedDate":"2026-02-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-02","defaultRemindTime":1772461800000,"name":"Principal Active High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-04","payableDate":"2026-03-02","currency":"USD","dateTimestamp":1772427600000,"payDate":"2026-03-04"},{"date":"2026-02-02","symbol":"YLD","amount":0.115854,"announcedDate":"2026-01-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-02","defaultRemindTime":1770042600000,"name":"Principal Active High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-04","payableDate":"2026-02-02","currency":"USD","dateTimestamp":1770008400000,"payDate":"2026-02-04"},{"date":"2025-12-29","symbol":"YLD","amount":0.138984,"announcedDate":"2025-12-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-29","defaultRemindTime":1767018600000,"name":"Principal Active High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-29","currency":"USD","dateTimestamp":1766984400000,"payDate":"2025-12-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"YLD\",market:\"US\",,,undefined,":[{"executeDate":"2016-06-01","recordDate":"2016-06-03","paymentDate":"2016-06-07","value":0.1333339,"currency":"USD"},{"executeDate":"2016-07-01","recordDate":"2016-07-06","paymentDate":"2016-07-08","value":0.0752768,"currency":"USD"},{"executeDate":"2016-08-01","recordDate":"2016-08-03","paymentDate":"2016-08-05","value":0.169666,"currency":"USD"},{"executeDate":"2016-09-01","recordDate":"2016-09-06","paymentDate":"2016-09-08","value":0.175499,"currency":"USD"},{"executeDate":"2016-10-03","recordDate":"2016-10-05","paymentDate":"2016-10-07","value":0.177417,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"YLD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"YLD\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2628479823","title":"Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628479823","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628479823?lang=en_us&edition=fundamental","pubTime":"2026-04-20 01:29","pubTimestamp":1776619740,"startTime":"0","endTime":"0","summary":"The one-year INFUSE study observed patient-reported migraine-related cognitive symptoms at baseline and changes over 6 months in those with at least one prior anti-calcitonin gene-related peptide  treatment failure. VALBY, Denmark, April 20, 2026 /PRNewswire/ -- H. Lundbeck A/S  today presentednew real-world 6-month results from the INFUSE study at the American Academy of Neurology  2026 Annual Meeting, underscoring the importance of evaluating the broad burden of migraine beyond headache and migraine frequency. Despite being among the most frequently reported symptoms by people living with migraine, cognition and brain fog have rarely been systematically studied. These patient-reported outcomes data highlight the opportunity to focus on elements of migraine burden that are meaningful to individuals living with migraine and report improvement of migraine-related cognitive symptoms after eptinezumab treatment.[1]. \"These real-world, patient-reported INFUSE data give greater insight into","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/lundbeck-presents-new-data-at-aan-2026-highlighting-real-world-changes-in-migraine-related-cognitive-symptoms-after-starting-vyepti-eptinezumab-302746650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","EC","YLD","BK4178","AAN","MMD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/YLD\",params:#limit:6,delay:false,,,undefined,":[]}}